Research Publications

High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial.

Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients.

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

Emerging clinical applications in cardiovascular pharmacogenomics.

The importance of phase information for human genomics.

Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.

The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?

Effect of direct-to-consumer genomewide profiling to assess disease risk.

9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response.

Digital medicine and the Scripps Translational Science Institute.